romidepsin CTCL
Selected indexed studies
- The discovery and development of romidepsin for the treatment of T-cell lymphoma. (Expert Opin Drug Discov, 2017) [PMID:28641053]
- Romidepsin for the treatment of T-cell lymphomas. (Am J Health Syst Pharm, 2013) [PMID:23784158]
- Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma. (Leuk Lymphoma, 2025) [PMID:40788987]
_Worker-drafted node — pending editorial review._
Connections
romidepsin CTCL is a side effect of
Sources
- The discovery and development of romidepsin for the treatment of T-cell lymphoma. (2017) pubmed
- Romidepsin for the treatment of T-cell lymphomas. (2013) pubmed
- Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma. (2025) pubmed
- Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. (2016) pubmed
- Targeting histone deacetylases in T-cell lymphoma. (2017) pubmed
- Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. (2024) pubmed
- Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. (2012) pubmed
- Romidepsin for cutaneous T-cell lymphoma. (2012) pubmed
- [Romidepsin (Istodax(®) for intravenous injection 10 mg): pharmacokinetics, pharmacodynamics and clinical study outcome]. (2018) pubmed
- Romidepsin for the treatment of cutaneous T-cell lymphoma. (2009) pubmed